Single centre experience on the use of low dose subcutaneous cytarabine in treatment of patients with high-risk myelodysplastic syndrome and acute myeloid leukaemia

被引：0
|
作者：
Schneider, T. [1 ]
Narayanan, S. [1 ]
机构：
[1] Univ Hosp Southampton NHS Fdn Trust, Dept Haematol, Southampton, Hants, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
161
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [11] Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism
    Buckstein, Rena
    LANCET HAEMATOLOGY, 2015, 2 (10): : E396 - E397
  • [12] Combination of fludarabine and cytarabine as induction treatment of poor prognosis myelodysplastic syndrome (MDS) and secondary acute myeloid leukaemia (sAML): a single centre experience
    Crotta, A.
    Tassara, M.
    Peccatori, J.
    Corti, C.
    Lunghi, F.
    Stanghellini, M. T. Lupo
    Bregni, M.
    Ciceri, F.
    Bernardi, M.
    LEUKEMIA RESEARCH, 2007, 31 : S124 - S125
  • [13] Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
    Ravandi, Farhad
    Assi, Rita
    Daver, Naval
    Benton, Christopher B.
    Kadia, Tapan
    Thompson, Philip A.
    Borthakur, Gautam
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina
    Takahashi, Koichi
    Kornblau, Steven
    DiNardo, Courtney D.
    Estrov, Zeev
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James
    Sharma, Padmanee
    Pierce, Sherry
    Pike, Allison
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    LANCET HAEMATOLOGY, 2019, 6 (09): : E480 - E488
  • [14] Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome
    Niessen, F. A.
    van Mourik, M. S. M.
    Bruns, A. H. W.
    Raijmakers, R. A. P.
    de Groot, M. C. H.
    van der Bruggen, T.
    ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL, 2020, 9 (01)
  • [15] Early discontinuation of empirical antibiotic treatment in neutropenic patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome
    F. A. Niessen
    M. S. M. van Mourik
    A. H. W. Bruns
    R. A. P. Raijmakers
    M. C. H. de Groot
    T. van der Bruggen
    Antimicrobial Resistance & Infection Control, 9
  • [16] Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia
    Zhang, Xi
    LANCET HAEMATOLOGY, 2023, 10 (03): : E159 - E160
  • [17] Low-dose Cytarabine plus Aclarubicin for Patients with Previously Untreated Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Ineligible for Standard-dose Cytarabine plus Anthracycline
    Fukushima, Toshihiro
    Kawabata, Hiroshi
    Sawaki, Toshioki
    Satoh, Tomomi
    Nakamura, Takuji
    Iwao, Haruka
    Nakajima, Akio
    Sakai, Tomoyuki
    Miki, Miyuki
    Fujita, Yoshimasa
    Tanaka, Masao
    Kawanami, Takafumi
    Masaki, Yasufumi
    Okazaki, Toshiro
    Umehara, Hisanori
    ANTICANCER RESEARCH, 2012, 32 (04) : 1347 - 1353
  • [18] SEQUENTIAL ALLOGENEIC TRANSPLANTATION IN ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROME: EXPERIENCE FROM A SINGLE CENTRE
    Jurado, Rebeca
    Morgades, Mireia
    de Jaureguizar, Alejandro
    Canelo, Marta
    Xicoy, Blanca
    Vives, Susana
    Josefa Jimenez, Maria
    Huguet, Maria
    Ferra, Christelle
    Maria Ribera, Josep
    Manuel Sancho, Juan
    Torrent, Anna
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 258 - 259
  • [19] Low-Dose Decitabine Combined with Modified Bucy Is More Effective Conditioning Regimen for High-Risk Patients with Acute Myeloid Leukaemia/Myelodysplastic Syndrome
    Tang, Xiaowen
    Cao, Jing
    Shi, Xiaojing
    Ge, Ling
    Sun, Aining
    Zhu, Xiaming
    Qiu, Huiying
    Jin, Zhengming
    Miao, Miao
    Fu, Chengcheng
    Ma, Xiao
    Chen, Feng
    Xue, Shengli
    Han, Yue
    Xue, Mengxing
    Mao, Xinliang
    Wu, Depei
    BLOOD, 2016, 128 (22)
  • [20] Cladribine, Idarubicin, Cytarabine (araC), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Reville, Patrick K.
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    DiNardo, Courtney D.
    Andreeff, Michael
    Daver, Naval
    Jain, Nitin
    Kornblau, Steven M.
    Jabbour, Elias
    Short, Nicholas J.
    Alvarado, Yesid
    Ohanian, Maro
    Bose, Prithviraj
    Masarova, Lucia
    Wang, Sa A.
    Tidwell, Rebecca S. S.
    Estrov, Zeev E.
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2020, 136
12345